Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in High-Risk Localized Prostate Cancer
NCT03035357Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of daratumumab in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Planned start Mar 2017; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03035357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035357.